Peer Review is the weekly biopharma jobs report from Endpoints News.
→ Argos’ Chief Medical Officer Lee Allen left last week, not long after the Durham, NC-based immunotherapy company slashed 46 of its 122-person staff back in March. Allen is now the CMO at Dova Pharmaceuticals.
→ Cambridge, MA’s Merrimack looked within and appointed Daryl Drummond as its new head of research. Drummond’s last post at the company was as VP of discovery and leader of the early-stage pipeline.
→ Brisbane, CA-based Aimmune Therapeutics named Eric Bjerkholt as CFO. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals.
→ New York, NY non-profit The Cancer Research Institute named Aiman Shalabi CMO. He was VP and head of immuno-oncology global medical affairs at AstraZeneca $AZN.
→ GI company Synergy Pharmaceuticals $SGYP named Gary Gemignani EVP and CFO. He replaces SVP of finance Bernard Denoyer, who is retiring. Gemignani was CEO and CFO of Biodel, which Albireo Pharma $ALBO acquired.
→ Allergan appointed Daphne Karydas to the role of SVP global IR and strategy. She’s a chemical engineer by training with a Harvard MBA. Prior to this she had been a process development engineer for Merck with stints at Goldman Sachs and JP Morgan.
→ ReForm Biologics, a Cambridge, MA-based formulations biotech, named John Sorvillo as their CEO. He joins from Amgen, where he was director of business development and licensing.
→ Drug delivery biotech Foresee Pharmaceuticals named Yisheng Lee CMO and David Lau SVP of NCE preclinical and clinical development. Lee will remain an attending physician at Northern California Children’s Hematology & Oncology Program. Lau was VP of preclinical safety assessment at Rigel Pharmaceuticals $RIGL.
→ Sunil Agarwal was named president of R&D at Juno Therapeutics $JUNOwith CMO Mark Gilbert, CSO Hy Levitsky and Liz Smith, head of regulatory and quality assurance, now reporting directly to him — an Endpoints News exclusive. The new R&D chief will also lead the new San Francisco organization.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.Free Subscription